Divarasib monotherapy demonstrated superior efficacy over first-generation KRAS G12C inhibitors, lowering the risk of disease progression or death by 42% and the overall risk of death by 44%, in the ...
In a prespecified interim analysis reviewed by the Independent Data Monitoring Committee (IDMC), HARMONi-GI1 met its primary ...
The phase III Krascendo 1 results demonstrate the potential for divarasib to become a new standard of care for people with ...
The cohort met its primary endpoint of major pathologic response, with 83% of patients having little or no cancer remaining ...
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that at the 2026 ...
JNJ-6143 is an investigational, once-daily, novel, small molecule designed to trigger cancer cell death through a targeted ...
BG-C477 is the first ADC to emerge from BeOne’s internal drug discovery organization. With a proprietary CEA (or CEACAM5) ...
ZW191 demonstrates compelling anti-tumor activity in heavily pretreated patients with platinum-resistant ovarian cancer ...
Upacicalcet is an investigational product candidate and has not been approved by the U.S. Food and Drug Administration.
Sefaxersen achieved a statistically significant 43.1% reduction in proteinuria, a key indicator of kidney damage, relative to ...
ORR at 6mg/kg dose in late-line CRC patients ARR-217 was generally well-tolerated ArriVent to host virtual webinar on Monday, ...
At the 2026 ESMO Annual Meeting, Zhejiang Wenda Pharmaceutical Technology Co., Ltd. ("Wenda Pharma") will publish the phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results